934586-49-9 Usage
General Description
1-(2-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)piperidine is a chemical compound with a complex molecular structure. It contains a piperidine ring, an ethyl chain, and a boron-containing group. The boron-containing group is specifically a 1,3,2-dioxaborolane, which consists of a boron atom and a cyclic five-membered ring. 1-(2-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)piperidine may have potential applications in organic synthesis, materials science, or pharmaceutical research, and its specific properties and uses would need to be further studied and elucidated. Additionally, its complex structure and the presence of boron suggest that it may have unique reactivity or coordination properties, which could make it of interest to researchers in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 934586-49-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,4,5,8 and 6 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 934586-49:
(8*9)+(7*3)+(6*4)+(5*5)+(4*8)+(3*6)+(2*4)+(1*9)=209
209 % 10 = 9
So 934586-49-9 is a valid CAS Registry Number.
InChI:InChI=1/C19H30BNO3/c1-18(2)19(3,4)24-20(23-18)16-8-10-17(11-9-16)22-15-14-21-12-6-5-7-13-21/h8-11H,5-7,12-15H2,1-4H3
934586-49-9Relevant articles and documents
Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutan
Wang, Aoli,Li, Xixiang,Chen, Cheng,Wu, Hong,Qi, Ziping,Hu, Chen,Yu, Kailin,Wu, Jiaxin,Liu, Juan,Liu, Xiaochuan,Hu, Zhenquan,Wang, Wei,Wang, Wenliang,Wang, Wenchao,Wang, Li,Wang, Beilei,Liu, Qingwang,Li, Lili,Ge, Jian,Ren, Tao,Zhang, Shanchun,Xia, Ruixiang,Liu, Jing,Liu, Qingsong
, p. 8407 - 8424 (2017/11/03)
FLT3-ITD mutant has been observed in about 30% of AML patients and extensively studied as a drug discovery target. On the basis of our previous study that ibrutinib (9) exhibited selective and moderate inhibitory activity against FLT3-ITD positive AML cel